Lunai Bioworks shares surge 11.02% intraday after receiving LOI for next-gen immune cell therapy showing complete regression of pancreatic tumors in preclinical models and AI-driven DCCT targeting low-survival cancers.

Lunai Bioworks surged 11.02% intraday after announcing its next-generation immune cell therapy received a Letter of Intent (LOI) for regulatory approval, achieving complete regression of primary and metastatic pancreatic tumors in preclinical models without recurrence. The company, which specializes in AI-driven drug discovery and bio-defense, highlighted its dendritic cell combination therapy (DCCT) targeting high-need solid tumors like pancreatic cancer (5-year survival rate of 13%) has advanced to Phase I trials following a successful pre-IND meeting.